仟源医药(300254) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥206,358,063.45, a decrease of 9.85% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥10,430,582.93, an increase of 509.67% year-on-year[5]. - The basic earnings per share for Q3 2023 was ¥0.0432, reflecting a 511.43% increase compared to the same period last year[5]. - Total operating revenue for Q3 2023 was ¥571,939,184.15, a decrease of 9.8% compared to ¥633,854,674.46 in Q3 2022[27]. - Net profit for Q3 2023 was ¥310,084.40, a significant improvement from a net loss of ¥2,867,785.25 in Q3 2022[28]. - The total comprehensive income for the period was -13,691,626.39 CNY, compared to -25,371,693.53 CNY in the previous period[29]. - The company reported a basic and diluted earnings per share of -0.0567 CNY, compared to -0.1077 CNY in the previous period[29]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,470,727,386.19, a decrease of 7.17% from the end of the previous year[5]. - The company's total assets decreased to ¥1,470,727,386.19 as of September 30, 2023, from ¥1,589,584,887.91 at the beginning of the year[25]. - Current assets totaled ¥451,392,998.11, down 11.1% from ¥508,026,427.66 at the start of the year[24]. - The company's total liabilities decreased to ¥740,769,174.79 from ¥859,936,760.91 at the beginning of the year, reflecting a reduction of 13.8%[25]. - Inventory increased to ¥122,347,593.44, up 18.5% from ¥103,257,824.28 at the beginning of the year[24]. - Long-term equity investments decreased to ¥81,076,473.96 from ¥86,026,457.77, a decline of 5.7%[24]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥10,837,856.01, down 82.50% year-on-year[5]. - The net cash flow from operating activities was 10,837,856.01 CNY, a significant decrease from 61,939,568.65 CNY in the previous period[32]. - Cash inflow from operating activities totaled 611,234,225.73 CNY, down from 689,602,195.84 CNY year-over-year[32]. - The net cash flow from investing activities was 87,462,022.18 CNY, improving from -23,188,936.91 CNY in the previous period[32]. - Cash outflow from financing activities was 308,238,248.20 CNY, compared to 194,303,468.77 CNY in the previous period[32]. - The total cash and cash equivalents at the end of the period were 140,607,269.29 CNY, down from 272,002,436.97 CNY in the previous period[32]. - The company received 86,700,000.00 CNY from borrowings, a decrease from 222,700,000.00 CNY in the previous period[32]. - The cash flow from operating activities outflow totaled 600,396,369.72 CNY, compared to 627,662,627.19 CNY in the previous period[32]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,047[14]. - The largest shareholder, Weng Zhangguo, holds 6.53% of shares, totaling 15,772,409 shares[14]. - The top ten shareholders include Zhaoqun, who holds 5.55% of shares, totaling 13,401,892 shares[14]. - The company has a total of 17,548,516 restricted shares, with 1,388,731 shares released during the period[18]. - The company has a total of 3,873,795 shares held by Huang Lequn under lock-up conditions[17]. - The company has a total of 10,051,419 shares held by Zhaoqun under lock-up conditions[17]. Investments and Asset Management - The company reported a 100% increase in held-for-sale assets, totaling ¥53,475,400, due to the planned sale of certain construction projects and intangible assets[9]. - Investment income for the year-to-date was ¥236,000, an increase of 178.67% compared to the previous year[10]. - The company experienced a 43.09% decrease in non-operating income year-to-date, totaling ¥12,260,200, primarily due to reduced support funds received[11]. - Cash flow from investing activities increased by 477.17% year-to-date, amounting to ¥87,462,000, mainly due to performance guarantees received[12]. Operational Costs - Total operating costs for Q3 2023 were ¥583,637,093.87, down 11.7% from ¥661,079,697.12 in the same period last year[27]. - The company reported a significant reduction in sales expenses to ¥239,903,789.55, down 22.3% from ¥308,822,286.41 in Q3 2022[28]. - Research and development expenses increased to ¥39,070,730.56, up 7.0% from ¥36,536,766.67 in the previous year[28]. Corporate Actions - The company plans to raise a total of up to 185 million RMB through a private placement of shares[19]. - The company has signed an asset sale agreement with Shanxi Shuangyan Pharmaceutical Co., Ltd.[19]. - The company has changed the collateral for bank credit to real estate owned by its wholly-owned subsidiary, Hangzhou Baoling Group Co., Ltd.[20]. - The company has approved changes to its drug research and development project funding from a previous stock issuance[21].